Morgan Stanley raised the firm’s price target on Rocket Lab (RKLB) to $20 from $18 and keeps an Equal Weight rating on the shares. After about a 360% run in 2024, the stock has underperformed the market by about 25% year-to-date in part on questions around the readiness of Neutron, Rocket Lab’s new medium-lift class rocket program, the analyst tells investors. However, the second half of 2025 target for Neutron’s debut reflects “a relatively modest delay,” says the analyst, who raised the firm’s target post-Q4 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RKLB:
- Hold Rating on Rocket Lab USA Amid Neutron Program Delays and Market Volatility
- Cathie Wood’s ARK Offloads Rocket Lab (NASDAQ:RKLB), Adds AVAV and GTLB
- Trump Wants to End CHIPS Act: TSM and INTC Could Be Biggest Losers
- Rocket Lab schedules first of multiple launches for iQPS
- Levi & Korsinsky LLP Reminds Shareholders of a Lead Plaintiff Deadline of April 28, 2025 in Rocket Lab Lawsuit – RKLB